Peptide Research Profile

TB-500

Thymosin Beta-4 Synthetic Analog — 43-Amino-Acid Protein

Evidence Grade: Early Human Data (Phase 2 Completed)

A synthetic analog of Thymosin Beta-4 (Tβ4), an endogenous 43-amino-acid protein involved in cell migration, wound healing, and tissue repair. Unlike most research peptides, Tβ4 has reached Phase 2 clinical trials for cardiac repair and chronic wound healing. However, Phase 3 was never pursued, and gray market "TB-500" may not be identical to the pharmaceutical-grade Tβ4 studied in trials.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. While early human trial data exists for Thymosin Beta-4, Phase 3 trials were never completed and the compound remains unapproved for any indication. Gray market TB-500 products may differ from pharmaceutical Tβ4. Always consult a qualified healthcare professional. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

43-AA Protein

Technically a small protein, not a peptide. Synthetic analog of endogenous Thymosin Beta-4, involved in actin dynamics and cell motility.

Molecular Weight

~4,921 Da

Substantially larger than typical peptides. Full sequence contains the actin-binding domain LKKTETQ (residues 17–23), considered essential for activity.

Primary Routes

SubQ · IM · IV

Subcutaneous most common off-label. Intravenous used in clinical trials. Not orally bioavailable due to size and lack of acid stability.

Human Trials

Phase 2

Phase 2 trials completed for cardiac repair (post-MI) and chronic wound healing. Phase 3 never initiated. No FDA approval for any indication.

Mechanism of Action

How TB-500 works

Thymosin Beta-4 is one of the most abundant intracellular proteins in mammalian cells, with a well-characterized primary function: sequestering monomeric G-actin to regulate the actin cytoskeleton. Beyond this housekeeping role, extracellular Tβ4 has been shown to promote cell migration, reduce inflammation, and activate progenitor cells. The mechanisms below reflect findings from multiple independent research groups, though some downstream effects (particularly the systemic ones) remain incompletely understood.

G-Actin Sequestration & Cytoskeletal Regulation

The primary intracellular function of Tβ4 is binding monomeric G-actin, preventing its polymerization into F-actin filaments. This maintains a reservoir of actin monomers available for rapid, directed polymerization when cells need to migrate, divide, or change shape. By modulating the G-actin/F-actin equilibrium, Tβ4 acts as a master regulator of cytoskeletal dynamics — the physical machinery cells use to move.

Tβ4 binds G-actin in a 1:1 complex via its central LKKTETQ motif (residues 17–23), which contacts the cleft between actin subdomains 1 and 3. The binding affinity (Kd ~0.5–2 µM) is moderate, allowing dynamic exchange. At ~500 µM intracellular concentration, Tβ4 sequesters approximately 50% of the unpolymerized actin pool. The N-terminal portion (residues 1–15) adopts a helical conformation upon binding, while the C-terminus remains largely unstructured. This sequestration prevents spontaneous nucleation while allowing rapid release of monomers to profilin-actin when Rho-GTPase signaling activates Arp2/3 or formins at the leading edge.

Cell Migration Promotion

When applied exogenously (as in TB-500 administration), Tβ4 promotes cell migration in endothelial cells, keratinocytes, and cardiac progenitor cells. This is the basis for its wound healing and tissue repair effects. The migrating cells move toward injury sites, where they participate in angiogenesis, re-epithelialization, and tissue remodeling. The extracellular signaling mechanism is not fully characterized — Tβ4 lacks a known cell-surface receptor.

Exogenous Tβ4 has been shown to activate Rac1 and Cdc42 GTPases in endothelial cells, promoting lamellipodia and filopodia formation. It also increases ILK (integrin-linked kinase) activity, which connects integrins to the actin cytoskeleton and promotes focal adhesion turnover — necessary for cell motility. In keratinocyte scratch assays, Tβ4 increases migration speed 2–3 fold. How exogenous Tβ4 enters cells or signals from outside remains unclear; some evidence suggests receptor-independent internalization, while other data indicates paracrine signaling through an unidentified surface receptor.

Anti-Inflammatory & Anti-Fibrotic Signaling

Tβ4 reduces inflammation through modulation of NF-κB signaling, decreasing expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). It also demonstrates anti-fibrotic effects, reducing collagen deposition and myofibroblast activation in models of cardiac, hepatic, and renal fibrosis. This dual action — reducing inflammation while preventing pathological scarring — is central to its therapeutic potential.

Tβ4 has been shown to inhibit NF-κB nuclear translocation by stabilizing IκBα, preventing its phosphorylation and proteasomal degradation. This reduces transcription of inflammatory mediators. Anti-fibrotic effects appear to involve suppression of TGF-β1/Smad3 signaling, which normally drives fibroblast-to-myofibroblast differentiation and excessive extracellular matrix deposition. In cardiac fibrosis models (Sopko et al., 2011), Tβ4 treatment reduced collagen I/III deposition by ~40%. In hepatic fibrosis models, it reduced α-SMA expression (a myofibroblast marker). Whether these effects are direct or secondary to improved vascularization and reduced ischemia remains debated.

VEGF Upregulation & Angiogenesis

Tβ4 promotes angiogenesis (new blood vessel formation) by upregulating vascular endothelial growth factor (VEGF) and promoting endothelial cell migration. This increased blood supply to injured tissues accelerates healing. The angiogenic effect has been observed consistently across wound healing, cardiac ischemia, and neurological injury models.

Tβ4 increases VEGF-A and Angiopoietin-1 expression, promoting endothelial cell proliferation and tube formation via PI3K/Akt signaling. It also upregulates HIF-1α under hypoxic conditions, amplifying the angiogenic response in ischemic tissue. In Matrigel plug assays, Tβ4 treatment increased vessel density 2–4 fold. The pro-angiogenic effect, while therapeutically desirable in ischemic tissue, carries the same theoretical concern as any VEGF-promoting agent regarding tumor vascularization. This has not been studied in cancer models.

Stem Cell & Progenitor Cell Activation

A distinctive feature of Tβ4 biology is its ability to activate resident progenitor cells. In the heart, Tβ4 reactivates epicardial progenitor cells (quiescent since embryonic development), causing them to differentiate into new cardiomyocytes and vascular smooth muscle cells. This has been demonstrated primarily in mouse models and represents the rationale behind the cardiac Phase 2 trials.

Smart et al. (2007, 2011) demonstrated that Tβ4 reactivates Wt1+ epicardial progenitor cells through Wnt/β-catenin signaling and Akt/eNOS pathways. These progenitors undergo epithelial-to-mesenchymal transition (EMT) and migrate into the myocardium, differentiating into de novo cardiomyocytes and coronary vasculature. Tβ4 also upregulates Notch signaling, which maintains progenitor self-renewal. Critically, this effect was most robust when Tβ4 was administered as a "priming" dose before injury (pre-treatment), which limits its clinical applicability for acute MI where prior treatment is impossible.

Neurogenesis & Neuroprotection

In brain injury and stroke models, Tβ4 promotes oligodendrocyte differentiation, axonal sprouting, and neuroblast migration from the subventricular zone to injury sites. It also reduces neuroinflammation and blood-brain barrier permeability after traumatic brain injury. These effects suggest potential applications in neurological recovery, though human data is limited to observational associations.

In rodent stroke models (Morris et al., 2010), Tβ4 treatment increased doublecortin+ neuroblasts migrating from the SVZ toward infarct areas, and promoted NG2+ oligodendrocyte progenitor differentiation into mature myelinating oligodendrocytes. Mechanistically, this involves p38 MAPK and Akt signaling, with Tβ4 reducing MMP-9 activity at the blood-brain barrier. In TBI models, Tβ4 reduced lesion volume and improved Morris water maze performance. These findings come from independent groups (Chopp lab, Henry Ford Hospital), providing important replication separate from the cardiac literature.

Delivery Routes

Administration methods

As a 43-amino-acid protein (~4.9 kDa), TB-500/Tβ4 is too large for oral bioavailability and requires parenteral administration. The clinical trials used intravenous infusion, while off-label use typically employs subcutaneous injection. Topical application has been studied for wound healing specifically.

Subcutaneous Injection

Primary · Off-Label Standard

Injected into the fatty tissue layer beneath the skin, typically in the abdomen or near the target area. This is the most common route in off-label use. Provides systemic distribution after absorption into lymphatic and capillary networks. Not the route used in clinical trials (which used IV), meaning pharmacokinetic behavior of SubQ TB-500 in humans is not well characterized.

Intramuscular Injection

Secondary · Limited Data

Injected directly into muscle tissue. Used by some practitioners for musculoskeletal injuries. Provides local tissue exposure plus systemic absorption. No comparative studies exist between IM and SubQ routes for Tβ4. Theoretical advantage of higher local concentration at muscle injury sites is plausible but unconfirmed.

Intravenous Infusion

Clinical Trial Route

Used in the RegeneRx Phase 2 cardiac repair trial (IV infusion of 1.2 g over 3 days). Provides immediate and complete bioavailability. Not practical for self-administration. This is the only route with formal human PK data, making it technically the best-characterized delivery method — but the one least accessible for off-label use.

Topical Application

Studied for Wounds Only

Applied directly to chronic wounds as a gel or solution. Used in the RegeneRx Phase 2 wound healing trials. Tβ4 penetrates wound beds and promotes local cell migration and angiogenesis. Not expected to provide meaningful systemic exposure. Limited to dermal wound applications; not a viable route for systemic effects.

Dosing Context

What the research used

Unlike BPC-157, Thymosin Beta-4 has actual human dosing data from clinical trials. However, the off-label TB-500 dosing protocols used in practice are not directly derived from these trials and may involve different formulations, purity levels, and delivery routes than what was studied.

Context	Dose	Route	Duration	Source
Cardiac repair post-MI (human Phase 2)	1.2 g total 400 mg IV daily × 3 days, single course	IV infusion	3 days	RegeneRx Phase 2 (NCT00378352)
Chronic wound healing (human Phase 2)	0.03% topical gel Applied to wound bed daily	Topical	28–84 days	RegeneRx wound trials
Cardiac progenitor activation (mouse)	150 µg/mouse ~6 mg/kg; pre-treatment before MI	IP	Single or 3-day pre-treatment	Smart et al., 2007
Neurological recovery (rat TBI/stroke)	6 mg/kg/day High dose relative to body weight	IP	14 days post-injury	Xiong et al., 2012
Common off-label (human)	2–5 mg, 2x/week Not based on clinical trial data; derived from practitioner anecdote and equine protocols	SubQ	4–8 weeks typical	No published source — practitioner consensus

Important Context

The clinical trials used pharmaceutical-grade Thymosin Beta-4 (full 43-AA sequence, GMP manufactured) via intravenous infusion at doses far higher than common off-label use. Gray market "TB-500" is sold as a synthetic analog, but its exact sequence, purity, and bioequivalence to pharmaceutical Tβ4 is generally unverified. Comparing off-label SubQ TB-500 at 2–5 mg to the clinical trial IV Tβ4 at 400 mg/day is not straightforward — the route, dose, and potentially the molecule itself may differ.

Evidence Summary

Observed effects & concerns

The evidence base for Tβ4 is more robust than most research peptides due to multiple independent research groups and completed Phase 2 trials. However, "Phase 2 completed" does not mean "proven effective" — the cardiac trial showed modest results insufficient to justify Phase 3, and gray market TB-500 may not replicate clinical-grade Tβ4 effects.

Observed Benefits

Wound Healing Acceleration

Accelerated closure of chronic wounds in Phase 2 human trials (topical). Robust preclinical data across multiple wound models showing enhanced keratinocyte migration, angiogenesis, and granulation tissue formation. The most well-supported therapeutic application.

Evidence: Phase 2 human (topical) + strong preclinical · Multiple independent groups

Cardiac Repair Post-MI

Phase 2 trial showed modest improvement in cardiac function markers after myocardial infarction. Mouse data showed epicardial progenitor activation and new cardiomyocyte formation. However, results were not strong enough for Phase 3 advancement.

Evidence: Phase 2 human (modest) + strong preclinical · Phase 3 not pursued

Anti-Fibrotic Effects

Reduced pathological fibrosis in cardiac, hepatic, and renal animal models. Decreased collagen deposition and myofibroblast activation. Potentially relevant for conditions involving tissue scarring and organ fibrosis.

Evidence: Strong preclinical (multiple models) · No human fibrosis data

Neurogenesis & Neural Recovery

Promoted oligodendrocyte differentiation, axonal remodeling, and neuroblast migration in rodent stroke and TBI models. Improved functional outcomes (motor and cognitive) in multiple studies from independent laboratories.

Evidence: Moderate preclinical (independent groups) · No human neurological data

Hair Regrowth

Stimulated hair follicle stem cell migration and increased hair growth in mouse models. Observed as a secondary finding in wound healing studies. Limited but consistent preclinical signal.

Evidence: Preclinical only · No human hair data

Side Effects & Concerns

Generally Well-Tolerated in Trials

Phase 2 cardiac and wound trials reported Tβ4 was generally well-tolerated. Mild adverse events included headache and nausea, reported at rates comparable to placebo. No serious adverse events attributed to Tβ4 in published trial data. However, trials were short-duration and small sample size.

Context: Phase 2 safety data only · Short duration · Small n

WADA Prohibited Substance

Thymosin Beta-4 is banned by the World Anti-Doping Agency (WADA) under section S2 (Peptide Hormones, Growth Factors, Related Substances). Detection methods exist. Use results in competition bans for tested athletes regardless of therapeutic intent.

Status: Banned in sport · Detectable in testing

Theoretical Tumor Promotion (Angiogenesis)

Tβ4's pro-angiogenic and cell migration effects are the same processes exploited by tumors for growth and metastasis. Some in vitro studies have shown Tβ4 overexpression correlates with tumor aggressiveness. No direct evidence of tumor induction, but cancer safety has never been formally studied.

Risk level: Theoretical · Not studied in cancer contexts

Gray Market Product Uncertainty

Gray market "TB-500" is marketed as a synthetic Tβ4 analog, but the exact sequence, folding, purity, and biological equivalence to pharmaceutical Tβ4 used in clinical trials is generally unverified. Some products may be truncated fragments. Third-party testing is inconsistent, and contamination or degradation is possible.

Risk level: Practical · Supply chain and identity risk

Unknown Long-Term Effects

The longest human exposure data comes from short-course Phase 2 trials (days to weeks). Effects of repeated, long-term Tβ4 administration on angiogenesis regulation, stem cell populations, and tissue remodeling over months or years are completely unknown. The typical off-label protocol (weeks to months) exceeds studied durations.

Risk level: Unknown · No chronic exposure data in humans

Key Studies

What the research actually shows

The Tβ4 literature benefits from contributions by multiple independent research groups (unlike BPC-157's single-lab dominance). Below are representative studies spanning the cardiac, wound healing, and neuroscience domains. Each illustrates both the promise and the limitations of the current evidence.

Animal Model · Cardiac Repair

Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

Bock-Marquette et al. · Nature · 2004 · Mouse MI model

What They Studied

Coronary artery ligation (myocardial infarction) in mice, with Tβ4 administered intraperitoneally. Outcomes: infarct size, cardiac function (echocardiography), cell survival, ILK activation. Also examined Tβ4 effects on cardiac cell migration in vitro.

What They Found

Tβ4 treatment reduced infarct size and improved cardiac function compared to controls. In vitro, Tβ4 promoted cardiomyocyte migration and survival via ILK/Akt signaling. Established Tβ4 as a candidate cardiac repair agent and initiated the clinical development program at RegeneRx.

Study Limitations

Mouse cardiac physiology differs substantially from human (heart rate ~600 bpm, different regenerative capacity). Tβ4 was given immediately after ligation — clinical MI patients present hours to days later. The subsequent Phase 2 human trial showed only modest benefit and did not advance to Phase 3, suggesting the mouse-to-human translation was weaker than hoped. The IP delivery route does not reflect practical human administration.

View on PubMed

Human Phase 2 · Wound Healing

Thymosin β4 promotes dermal healing

Philp et al. · Expert Opin Biol Ther · 2004 / RegeneRx Phase 2 data

What They Studied

Topical Tβ4 (0.03% gel) applied to chronic, non-healing wounds (venous stasis ulcers and pressure ulcers) in human patients. Assessed wound closure rate, granulation tissue formation, and safety over treatment periods of 28–84 days.

What They Found

Tβ4-treated wounds showed accelerated healing compared to standard care. Increased granulation tissue formation and wound closure rates observed. Well-tolerated with no drug-related serious adverse events. Provided clinical proof-of-concept for Tβ4 in wound repair, though sample sizes were small.

Study Limitations

Small sample sizes in Phase 2 (typically 30–72 patients). Open-label or partially blinded designs in early trials. Topical application to wounds does not inform us about systemic SubQ use for musculoskeletal injuries. Chronic wound healing has high placebo/standard-care variability. RegeneRx did not advance to large Phase 3 trials, possibly reflecting investor/funding decisions as much as efficacy concerns. Full trial data not published in peer-reviewed journals in all cases.

View on PubMed

Animal Model · Cardiac Progenitors

Thymosin β4 is essential for coronary vessel development and promotes neovascularization via adult epicardium

Smart et al. · Nature · 2007 (+ follow-up 2011) · Mouse models

What They Studied

Role of Tβ4 in embryonic coronary vessel development and adult epicardial progenitor reactivation. Tβ4 knockout embryos, plus Tβ4 pre-treatment before MI in adult mice. Outcomes: epicardial cell activation, EMT, differentiation into cardiomyocytes and vascular cells.

What They Found

Tβ4 is required for coronary vessel development during embryogenesis. In adults, Tβ4 pre-treatment reactivated quiescent epicardial progenitors (Wt1+ cells), inducing them to undergo EMT and differentiate into de novo cardiomyocytes and coronary vasculature. This "priming" effect provided cardioprotection against subsequent MI.

Study Limitations

The key finding — epicardial progenitor activation — required pre-treatment before injury. This is not clinically applicable for heart attacks (patients cannot be pre-treated). The 2011 follow-up showed some post-MI benefit, but it was weaker than the pre-treatment effect. Mouse cardiac regenerative capacity exceeds human. The degree of new cardiomyocyte formation from epicardial progenitors in adult humans (if any) is unknown and controversial. Independent replication of the magnitude of these effects has been limited.

View on PubMed

What We Don't Know

Critical research gaps

Despite more clinical development than most research peptides, Tβ4/TB-500 has significant unresolved questions. The completion of Phase 2 trials without advancement to Phase 3 is itself informative — it suggests the signal was not strong enough to justify large, expensive confirmatory trials. The gap between "studied in trials" and "proven effective" is substantial.

Phase 3 Never Completed for Any Indication

RegeneRx Biopharmaceuticals completed Phase 2 trials for cardiac repair and wound healing but never advanced to Phase 3. The cardiac trial showed modest benefit insufficient to attract Phase 3 funding. Without Phase 3 data, efficacy remains unconfirmed at the standard required for drug approval. "Phase 2 completed" means "initial signal detected in a small trial" — not "proven to work."

TB-500 (Gray Market) vs. Pharmaceutical Tβ4 Identity Gap

The clinical trials used GMP-manufactured, full-length 43-amino-acid Thymosin Beta-4. Gray market "TB-500" is marketed as a synthetic analog but may be a truncated fragment, may have different folding, and is generally not verified for bioequivalence. Assuming gray market TB-500 produces the same effects as clinical-grade Tβ4 is an unvalidated assumption. No head-to-head comparison has been published.

No Pharmacokinetics for Subcutaneous Route in Humans

Human PK data exists only for intravenous Tβ4 (from the cardiac trial). The SubQ route used in off-label practice has no published human PK data. We do not know what plasma levels are achieved, what the bioavailability is relative to IV, or how the absorption profile compares. Off-label dosing (2–5 mg SubQ) cannot be meaningfully compared to the clinical IV dose (400 mg/day) without this data.

Cancer Safety Not Studied

Tβ4 overexpression has been correlated with tumor aggressiveness and metastatic potential in several cancers (thyroid, colorectal, melanoma). Whether exogenous Tβ4 administration promotes tumor growth, facilitates metastasis, or has no effect on existing malignancies has never been tested. Given its pro-angiogenic and cell-migration-promoting properties, this gap is concerning and would normally be addressed before widespread use.

Long-Term Safety Unknown

Clinical trial exposure was days (cardiac) to weeks (wound healing). Off-label protocols typically run 4–8 weeks but some users continue for months. The effects of sustained exogenous Tβ4 on stem cell populations, angiogenesis regulation, and tissue remodeling homeostasis over extended periods are entirely unknown. No registry or long-term follow-up data exists.

Mechanism for Systemic Effects of Local Protein Unclear

Tβ4 is one of the most abundant intracellular proteins (~500 µM concentration inside cells). How adding small exogenous amounts (nanomolar range in plasma after injection) produces systemic therapeutic effects against this high endogenous background is mechanistically unclear. The extracellular signaling pathway — including whether a cell-surface receptor exists — has not been definitively identified.

References

Primary sources

1. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PubMed

2. Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PubMed

3. Smart N, Bollini S, Dubé KN, et al. De novo cardiomyocytes from within the activated adult heart after injury. Nature. 2011;474(7353):640-644. PubMed

4. Philp D, Badamchian M, Scheremeta B, et al. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PubMed

5. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. PubMed

6. Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin β4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682. PubMed

7. Xiong Y, Mahmood A, Zhang Y, et al. Thymosin β4 treatment of traumatic brain injury in the rat. J Neurosurg. 2012;116(5):1081-1092. PubMed

8. Sopko N, Qin Y, Engber A, et al. Significance of thymosin β4 and implication of PINCH and ILK in its antifibrotic effect in cardiac fibroblasts in vitro. J Mol Cell Cardiol. 2011;51(3):263-270. PubMed

All Tβ4 on PubMed → ← Back to Research Library